Small-diameter synthetic vascular grafts have high failure rate and tissue-engineered blood vessels are limited by the scalability. Here we engineered bioactive materials for in situ vascular tissue engineering, which recruits two types of endogenous progenitor cells for the regeneration of blood vessels. Heparin was conjugated to microfibrous vascular grafts to suppress thrombogenic responses, and stromal cell-derived factor-1α (SDF-1α) was immobilized onto heparin to recruit endogenous progenitor cells. Heparin-bound SDF-1α was more stable than adsorbed SDF-1α under both static and flow conditions. Microfibrous grafts were implanted in rats by anastomosis to test the functional performance. Heparin coating improved the short-term patency, and immobilized SDF-1α further improved the long-term patency. SDF-1α effectively recruited endothelial progenitor cells (EPCs) to the luminal surface of the grafts, which differentiated into endothelial cells (ECs) and accelerated endothelialization. More interestingly, SDF-1α increased the recruitment of smooth muscle progenitor cells (SMPCs) to the grafts, and SMPCs differentiated into smooth muscle cells (SMCs) in vivo and in vitro. Consistently, SDF-1α-immobilized grafts had significantly higher elastic modulus. This work demonstrates the feasibility of simultaneously recruiting progenitor cells of ECs and SMCs for in situ blood vessel regeneration. This in situ tissue engineering approach will have broad applications in regenerative medicine.

SUMMARYConflict procedures can be used to study the receptor mechanisms underlying the anxiolytic effects of benzodiazepines and other GABA A receptor modulators. In the present study, we first determined the efficacy and binding affinity of the benzodiazepine diazepam and recently synthesized GABA A receptor modulators JY-XHe-053, XHe-II-053, HZ-166, SH-053-2'F-S-CH 3 and SH-053-2'F-R-CH 3 at GABA A receptors containing α1, α2, α3 and α5 subunits. Results from these studies suggest that each compound displayed lower efficacy at GABA A receptors containing α1 subunits and varying degrees of efficacy and affinity at GABA A receptors containing α2, α3 and α5 subunits. Next, we assessed their anxiolytic effects using a rhesus monkey conflict procedure in which behavior was maintained under a fixed-ratio schedule of food delivery in the absence (nonsuppressed responding) and presence (suppressed responding) of response-contingent electric shock. Relatively non-selective compounds, such as diazepam and JY-XHe-053 produced characteristic increases in rates of suppressed responding at low to intermediate doses and decreased the average rates of non-suppressed responding at higher doses. XHe-II-053 and HZ-166 also produced increases in suppressed responding at low to intermediate doses, but were ineffective at decreasing rates of non-suppressed responding, consistent with their relatively low efficacy at GABA A receptors containing α1 and α5 subunits. In contrast, SH-053-2'F-S-CH 3 and SH-053-2'F-R-CH 3 produced only partial increases in suppressed responding and were ineffective on non-suppressed responding, consistent with their profiles as partial agonists at GABA A receptors containing α2, α3 and α5 subunits. These behavioral effects suggest that the anxiolytic and rate-reducing effects of GABA A receptor positive modulators are dependent on their relative efficacy and affinity at different GABA A receptor subtypes.

A novel N-¿2-amino-4-methyl[(pyrrolo[2, 3-d]pyrimidin-5-yl)ethyl]benzoyl¿-L-glutamic acid (3a) was designed and synthesized as a potent dual inhibitor of thymidylate synthase (TS) and dihydrofolate reductase (DHFR) and as an antitumor agent. Compound 3b, the N7-benzylated analogue of 3a, was also synthesized as an antitumor agent. The synthesis of 3a was accomplished via a 12-step sequence which involved the synthesis of 2-amino-4-methylpyrrolo[2,3-d]pyrimidine (10) in 5 steps from 2-acetylbutyrolactone. Protection of the 2-amino group of 10 and regioselective iodination at the 5-position followed by palladium-catalyzed coupling afforded intermediate 14 which was converted to 3a by reduction and saponification. Similar synthetic methodology was used for 3b. X-ray crystal structure of the ternary complex of 3a, DHFR, and NADPH showed that the pyrrolo[2, 3-d]pyrimidine ring binds in a "2,4-diamino mode" in which the pyrrole nitrogen mimics the 4-amino moiety of 2,4-diaminopyrimidines. This is the first example of a classical pyrrolo[2,3-d]pyrimidine antifolate shown to have this alternate mode of binding to DHFR. Compounds 3a and 3b were more inhibitory than LY231514 against TS from Lactobacillus casei and Escherichia coli. Analogue 3a was also more inhibitory against DHFR from human, Toxoplasma gondii, and Pneumocystis carinii. Evaluation of 3a against methotrexate (MTX)-resistant cell lines with defined mechanisms indicated that cross-resistance of 3a was much lower than that of MTX. Metabolite protection studies and folylpoly-gamma-glutamate synthetase studies suggest that the antitumor activity of 3a against the growth of tumor cells in culture is a result of dual inhibition of TS and DHFR. Compound 3a inhibited the growth of CCRF-CEM and FaDu cells in culture at ED(50) values of 12.5 and 7.0 nM, respectively, and was more active against FaDu cells than MTX. In contrast, compound 3b was inactive against both cell lines. Compound 3a was evaluated in the National Cancer Institute in vitro preclinical antitumor screening program and afforded IG(50) values in the nanomolar range against a number of tumor cell lines.

No abstract

The first total synthesis of (+)-Na-methyl-16-epipericyclivine (9) was completed [from d-(+)-tryptophan methyl ester] in an overall yield of 42% (eight reaction vessels). The optical rotation [[alpha]D +22.8 (c 0.50, CHCl3)] obtained on this material confirmed that the reported optical rotation [[alpha]D 0 (c 0.50, CHCl3)]47 was biogenetically unreasonable. The total syntheses of (+)-vellosimine, (+)-normacusine B, (-)-alkaloid Q3, (-)-panarine, and (+)-Na-methylvellosimine are also described. Moreover, a mixed sample (1:1) of synthetic (-)-panarine and natural (-)-panarine yielded only one set of signals in the 13C NMR; this indicated that the two compounds are identical and further confirmed the correct configuration of (+)-vellosimine, (+)-normacusine B, and (-)-alkaloid Q3. In this approach, the key templates, (-)-Na-H,Nb-benzyltetracyclic ketone 15a and (-)-Na-methyl,Nb-benzyltetracyclic ketone 43 were synthesized on multihundred gram scale by the asymmetric Pictet-Spengler reaction and a stereocontrolled Dieckmann cyclization via improved sequences. An intramolecular palladium (enolate-mediated) coupling reaction was employed to introduce the C(19)-C(20) E-ethylidene function in the sarpagine alkaloids for the first time in stereospecific fashion.

Postoperative infections remain a risk factor that leads to failures in oral and maxillofacial artificial bone transplantation. This study aimed to synthesize and evaluate a novel hydroxyapatite whisker (HAPw) / nano zinc oxide (n-ZnO) antimicrobial bone restorative biomaterial. A scanning electron microscope (SEM), energy dispersive spectroscopy (EDS) and x-ray diffraction (XRD) were employed to characterize and analyze the material. Antibacterial capabilities against Staphylococcus aureus, Escherichia coli, Candida albicans and Streptococcus mutans were determined by minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC), and kinetic growth inhibition assays were performed under darkness and simulated solar irradiation. The mode of antibiotic action was observed by transmission electron microscopy (TEM) and confocal laser scanning microscopy (CLSM). The MIC and MBC were 0.078-1.250 mg ml(-1) and 0.156-2.500 mg ml(-1), respectively. The inhibitory function on the growth of the microorganisms was achieved even under darkness, with gram-positive bacteria found to be more sensitive than gram-negative, and enhanced antimicrobial activity was exhibited under simulated solar excitation compared to darkness. TEM and CLSM images revealed a certain level of bacterial cell membrane destruction after treatment with 1 mg ml(-1) of the material for 12 h, causing the leakage of intracellular contents and bacteria death. These results suggest favorable antibiotic properties and a probable mechanism of the biomaterial for the first time, and further studies are needed to determine its potential application as a postoperative anti-inflammation method in bone transplantation.

In dental clinic, unsatisfactory management of the dentin surface after dentin exposure often leads to the occurrence of dentin hypersensitivity and caries. Current approaches can occlude the tubules on the dentin surface to relieve dentin hypersensitivity; however, the blocked tubules are generally weak in combating daily tooth erosion and abrasion. Moreover, cariogenic bacteria, such as Streptococcus mutans, produce biofilm on the dentin surface, causing caries and compromising the tubules' sealing efficacy. To overcome this problem, the present study focused on establishing a versatile biomaterial, epigallocatechin-3-gallate-encapsulated nanohydroxyapatite/mesoporous silica nanoparticle (EGCG@nHAp@MSN), for therapeutic management of the dentin surface. The effectiveness of the biomaterial on dentinal tubule occlusion, including resistances against acid and abrasion, was evaluated by field-emission scanning electron microscopy (FESEM) and dentin permeability measurement. The inhibitory capability of the biomaterial on S. mutans biofilm formation was investigated by confocal laser scanning microscopy (CLSM), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, colony forming units (CFU) counts, and FESEM. Results demonstrated for the first time that the use of EGCG@nHAp@MSN on the dentin surface was capable of effectively occluding dentinal tubules, reducing dentin permeability, and achieving favorable acid- and abrasion-resistant stability. Furthermore, EGCG@nHAp@MSN held the capability to continuously release EGCG, Ca, and P, and significantly inhibit the formation and growth of S. mutans biofilm on the dentin surface. Thus, the development of EGCG@nHAp@MSN bridges the gap between multifunctional concept and dental clinical practice and is promising in providing dentists a therapeutic strategy for the management of the dentin surface to counter dentin hypersensitivity and caries.

No abstract